GermanyGermany

Betting on biotech for CO2 conversion solutions

01.02.2010

Essen – Germany’s largest power supplier RWE is teaming up with industrial biotechnology specialist Brain AG. Together the two want to develop tailor-made microbes able to remove carbon dioxide from the gas mixture emitted by lignite-fired power stations. The partners say the partnership will explore and engineer new enzymes, along with innovative synthesis and pathway routes, adding that the new designer organisms now being explored could produce building and insulating materials as well as fine and specialty chemicals. An experimental plant is to be located at RWE Power’s Coal Innovation Centre at its Cologne power plant site. Brain’s Research Director Jürgen Eck believes “a new era of CO2 conversion” could be opened up by the co-operation. “The co-operation is an important step towards using biology to tackle technical challenges,” added Dr. Johannes Ewers, New Technology/Carbon Capture & Storage Manager at RWE Power. The energy supplier already runs an algae project that uses plant matter to mop up carbon dioxide, converting it into biomass. However, that process suffers from capacity problems, as it is restricted by a low conversion rate. Bacteria or certain fungi, on the other hand, offer much more active metabolic pathways that can be exploited to help solve some of those problems. RWE Power claims it will invest more than a90m into exploring solutions for more efficient CO2 conversion.

GermanyGermany

07.03.2012

The first of February marked a milestone for Leverkusen-based Bio­frontera AG in more ways than one. It was the first day that Ameluz, the firm’s first approved product, could be sold in German pharmacies. It was also the date...

GermanyGermany

07.03.2012

Darmstadt – German pharmaceutical and chemical company Merck KGaA has set a downbeat tone for 2012. CEO Karl-Ludwig Kley said the recently launched cost-cutting programme and tough economic conditions will weigh on profits this...

GermanyGermany

05.03.2012

Mainz/Leuna – Two biotech concepts were amongst the winners of the recent third round of the Excellence Cluster initiative, which is funded by the German Ministry for Research. In Mainz the champagne corks popped especially loud...

GermanyGermany

05.03.2012

German Merck KGaA has closed a licencing agreement with US-based Threshold Pharmaceuticals Inc. The cooperation centres around the hypoxia­-activated drug TH-302, which is currently being studied in a global Phase III study....

GermanyGermany

29.02.2012

Munich – Looking back with satisfaction and bent on a prize for good behaviour, German biopharmaceutical company Wilex AG reported yesterday on the fiscal year 2011 and outlined the shores in sight. The 2011 total revenue was...

GermanyGermany

17.02.2012

Brussels – European cartilage researchers intensify their cooperation. The 'gristle network' comprises scientists from Belgium, France, Germany and Luxembourg. Its members plan to meet regularly to exchange views and information...

27.01.2012

Thousand Oaks/Munich - Bling bling for blinatumomab. It is a compliment for the European life sciences scene and sad news at the same time. Amgen Inc., the world's largest biotechnology company, agreed to buy Micromet Inc., an...

GermanyGermany

20.01.2012

Martinsried - SHELTER is responsible for the fact that the stocks of 4SC behaved like a rodeo horse on Thursday. The shares rose in several stages up to 63%, only to settle at a mere 43% rise at the end of the day. SHELTER is a...

GermanyGermany

17.01.2012

Ludwigshafen – BASF Plant Science GmbH, the agrochemistry and biotech arm of the world-largest chemistry company, thinks that it has outstayed its welcome in Europe. Over the next two years, most of the green biotechnology...

GermanyGermany

10.01.2012

Munich - It is the accolade for Micromet. The German company, which is listed on the U.S. stock exchange, announced today that it has entered into a Cooperative Research and Development Agreement (CRADA) with the renowned US...

Displaying results 1 to 10 out of 454

1-10 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/news/messages-archive/archive-germany/article/betting-on-biotech-for-co2-conversion-solutions.html

Image Gallery

Stock list

All quotes

TOP

  • MORPHOSYS (D)62.00 EUR11.8%
  • BIOINVENT INTERNATIONAL AB (S)2.96 SEK10.9%
  • BAVARIAN NORDIC (D)14.56 EUR10.3%

FLOP

  • CYTOS (CH)0.17 CHF-26.1%
  • XENETIC BIOSCIENCES (UK)6.00 GBP-14.3%
  • FLAMEL TECHNOLOGIES (F)9.94 USD-9.7%

TOP

  • CO.DON (D)3.30 EUR88.6%
  • BIOTECH PHARMACON (N)17.50 NOK59.1%
  • WILEX (D)0.92 EUR50.8%

FLOP

  • CYTOS (CH)0.17 CHF-94.1%
  • BIONOR PHARMA (N)2.11 NOK-49.0%
  • GW PHARMACEUTICALS (UK)219.25 GBP-39.6%

TOP

  • SILENCE THERAPEUTICS (UK)256.00 GBP6143.9%
  • IXICO (UK)71.50 GBP807.4%
  • PLETHORA (UK)10.62 GBP585.2%

FLOP

  • CYTOS (CH)0.17 CHF-95.8%
  • EVOCUTIS (UK)0.22 GBP-92.7%
  • AGENNIX (D)0.04 EUR-80.0%

No liability assumed, Date: 16.04.2014

Current issue

All issues

Product of the week

Products

Events

All Events

Partner-Events

München

BioVaria 2014

Frankfurt am Main

7th DVFA Life Science Conference

White Paper